Corcept Therapeutics Incorporated (CORT)

Market Cap	2.68B
Revenue (ttm)	397.62M
Net Income (ttm)	116.80M
Shares Out	107.13M
EPS (ttm)	1.00
PE Ratio	24.98
Forward PE	23.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	301,902
Open	24.82
Previous Close	24.94
Day's Range	24.67 - 25.16
52-Week Range	15.83 - 30.14
Beta	0.55
Analysts	Buy
Price Target	32.81 (+31.3%)
Earnings Date	Nov 3, 2022

About CORT

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients wi...

• Industry: Pharmaceuticals
• Founded: 1998
• CEO: Joseph Belanoff
• Employees: 238
• Stock Exchange: NASDAQ
• Ticker Symbol: CORT

Full Company Profile

Financial Performance

In 2021, CORT's revenue was $365.98 million, an increase of 3.42% compared to the previous year's $353.87 million. Earnings were $112.51 million, an increase of 6.13%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CORT stock is "Buy." The 12-month stock price forecast is 32.81, which is an increase of 31.35% from the latest price.

Price Target

$32.81

(31.35% upside)

Analyst Consensus: Buy

Stock Forecasts